ContraVir Pharmaceuticals, Inc. (CTRV) Set to Shake Up HBV Therapy Market with Combination Therapy Based on CMX157 & CRV431
A constant theme that comes up in and often dominates the leading edge of the biopharma sector is the building of better mousetraps. This is certainly the case for New Jersey-based biopharma developer ContraVir Pharmaceuticals (NASDAQ: CTRV), whose phase 2a clinical antiviral candidate CMX157 (http://nnw.fm/3nDCh) is knocking loudly on the door of Gilead Sciences’ (NASDAQ: GILD) Viread® (TDF, or tenofovir disoproxil fumarate) in chronic hepatitis B virus (HBV). Coming out of the box strong after notably successful phase 1 safety and efficacy trials, ContraVir was quite proud to recently announce (http://nnw.fm/rU7We) that the ongoing head-to-head phase 2a (multiple ascending dose)…